Form 4: Ovid Therapeutics Director Karen Bernstein Acquires 45,000 Stock Options

Ovid Therapeutics Inc. Director Karen Bernstein has acquired 45,000 stock options with an exercise price of $0.57, set to vest in full by February 20, 2026.

Summary

• Karen Bernstein, a Director of Ovid Therapeutics Inc. (OVID), acquired 45,000 stock options.
• The acquired stock options have an exercise price of $0.57 per share.
• These options are scheduled to vest in full on February 20, 2026, contingent on her continuous service through that date.
• The stock options have an expiration date of February 19, 2035.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged acquisition.

Sentiment

Score: 7

Explanation: The acquisition of stock options by a director can be viewed positively as it aligns their interests with shareholders and may signal confidence in the company's future, especially when executed under a 10b5-1 plan.

Positives

• The acquisition of 45,000 stock options by Director Karen Bernstein may signal confidence in the company's future performance and aligns her interests with shareholder value.
• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-planned, non-discretionary acquisition rather than an opportunistic trade.

Risks

• The value of the stock options is contingent on Ovid Therapeutics Inc.'s common stock price exceeding the $0.57 exercise price.
• The vesting of the options is subject to the reporting person's continuous service through February 20, 2026, meaning the options could be forfeited if service ceases before that date.

Future Outlook

This document primarily reports an insider transaction and does not contain forward-looking statements or guidance about the company's future performance or strategic outlook.

Industry Context

The grant of stock options to directors is a standard practice in corporate compensation across various industries, designed to align management's interests with shareholder value. This specific filing reflects an individual equity award rather than a broader industry trend or operational update.

Comparison to Industry Standards

• The grant of 45,000 stock options with a $0.57 exercise price to a director is a common form of equity compensation.
• To assess its relative generosity or standard practice, this specific award would need to be compared against Ovid Therapeutics' peer group's compensation policies and typical equity grants for directors.

Corporate Governance

Related Party Transactions

• The acquisition of stock options by Karen Bernstein, a Director of Ovid Therapeutics Inc., constitutes a related party transaction as it involves an equity grant from the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant of options aligns the director's financial interests with those of shareholders, as the options gain value only if the company's stock price increases, potentially incentivizing performance.

Next Steps

• The acquired stock options are scheduled to vest in full on February 20, 2026, subject to the reporting person's continuous service.

Key Dates

Keywords

Ovid Therapeutics, OVID, SEC Form 4, Stock Options, Insider Trading, Director Compensation, Karen Bernstein, Equity Grant, Rule 10b5-1